International Journal of Pancreatology

, Volume 17, Issue 2, pp 197–201 | Cite as

Long-term effects of alloxan in mice

  • Bo Ahrén
  • Göran Sundkvist


The long-term effects of subdiabetogenic doses of alloxan monohydrate (<70 mg/kg) were studied in the mouse. When injected intravenously at 50 and 60 mg/kg, alloxan induced a marked albeit transient hyperglycemia; plasma levels gradually declined after 15 d and were normal after 60 d in 20 of 31 animals. After injection of alloxan at the dose of 40 mg/kg, only a slight transient hyperglycemia was seen during the first 15 d. At 2 mo after alloxan injection, however, glucose- and carbachol-stimulated insulin secretion were markedly impaired in all animals treated with alloxan, including those with normoglycemia. The pancreatic content of insulin was significantly reduced at 2 mo after treatment of alloxan at 50 or 60 mg/kg, but, however, not after 40 mg/kg. It is concluded that (1) Subdiabetogenic doses of alloxan (50 and 60 mg/kg) induce a persistent hyperglycemia only in approx 25% of the animals; (2) The insulin secretory responses to glucose and carbachol are impaired after alloxan treatment; and (3) Alloxan-induced B-cell toxicity is evident also in animals not developing permanent diabetes. Hence, although a repair process may be initiated after alloxan to normalize the hyperglycemia, insulin secretion and pancreatic insulin content do not normalize.

Key Words

Diabetes alloxan insulin secretion mice 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rerup CC. Drugs producing diabetes through damage of the insulin secreting cells.Pharmacol Rev 1970; 22: 485–518.PubMedGoogle Scholar
  2. 2.
    Lenzen S, Mirzaie-Petri M. Inhibition of glucokinase and hexokinase from pancreatic B-cells and liver by alloxan, alloxantin, dialuric acid, and t-butylhydroperoxide.Biomed Res 1991; 12: 297–307.Google Scholar
  3. 3.
    Dunn JS, Kirkpatrick J, McLetchie NGB, Telfer SV. Necrosis of the islets of Langerhans produced experimentally.J Pathol Bact 1943; 55: 245–257.CrossRefGoogle Scholar
  4. 4.
    Malaisse WJ, Malaisse-Lagae F, Sener A, Pipeleers DG. Determinants of the selective toxicity of alloxan of the pancreatic B-cell.Proc Natl Acad Sci USA 1982, 79: 927–930.PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen G, Heikkila RE. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytoptoxic agents.J Biol Chem 1974; 249: 2447–2452.PubMedGoogle Scholar
  6. 6.
    Grankvist K, Marklund S, Töljedal IB. Superoxide dismutase is a prophylactic against alloxan diabetes.Nature 1981; 294: 158–160.PubMedCrossRefGoogle Scholar
  7. 7.
    Malaisse WJ. Alloxan toxicity to the pancreatic B-cell. A new hypothesis.Biochem Pharmacol 1982; 31: 3527–3534.PubMedCrossRefGoogle Scholar
  8. 8.
    Abdel-Rahman MS, Elrakhawy FI, Iskander FA. Protection of B cells against the effect of alloxan.Toxicol Lett 1992; 63: 155–164.PubMedCrossRefGoogle Scholar
  9. 9.
    Lenzen S, Panten U. Alloxan: history and mechanism of action.Diabetologia 1988; 31: 337–342.PubMedCrossRefGoogle Scholar
  10. 10.
    Yamamoto H, Uchigata Y, Okamoto H. Streptozotocin and alloxan induce DNA-strand breaks and poly-(ADP-ribose) synthetase in pancreatic islets.Nature 1981; 294: 284,285.PubMedCrossRefGoogle Scholar
  11. 11.
    Lundquist I, Rerup C. On the development of alloxan diabetes in mice.Eur J Pharmacol 1967; 2: 35–41.PubMedCrossRefGoogle Scholar
  12. 12.
    Rerup C, Tarding F. Streptozotocin- and alloxan-diabetes in mice.Eur J Pharmacol 1969; 7: 89–96.PubMedCrossRefGoogle Scholar
  13. 13.
    Jansson L, Sandler S. Alloxan-induced diabetes in the mouse: time course of pancreatic B-cell destruction as reflected in an increased islet vascular permeability.Virchows Arch A 1986; 410: 17–21.CrossRefGoogle Scholar
  14. 14.
    Eizirik DL, Sandler S. Functional restoration of cultured mouse pancreatic islets and in vitro exposure to alloxan.Pharmacol Toxicol 1988; 63: 396–399.PubMedCrossRefGoogle Scholar
  15. 15.
    Junod A, Lambert AE, Stauffacher W, Renold AE. Diabetogenic action of streptozotocin: relationship of dose and metabolic response.J Clin Invest 1969; 48: 2129–2139.PubMedCrossRefGoogle Scholar
  16. 16.
    Ar’Rajab A, Ahrén B. Long-term diabetogenic effect of streptozotocin in rats.Pancreas 1993; 8: 50–57.PubMedCrossRefGoogle Scholar
  17. 17.
    Eizirik DL, Sandler S. Function and metabolism of pancreatic a-cells maintained in culture following experimentally induced damage.Pharmacol Toxicol 1989; 65: 163–168.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1995

Authors and Affiliations

  • Bo Ahrén
    • 1
  • Göran Sundkvist
    • 2
  1. 1.Department of MedicineLund UniversityMalmöSweden
  2. 2.Department of EndocrinologyLund UniversityMalmöSweden

Personalised recommendations